搜尋結果
e. The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, [33] [34] [35] using as a vector the modified chimpanzee ...
- AU: B1
- SARS-CoV-2
- Vaxzevria, Covishield
- Viral vector
Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm.[1][2] They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining ...
- .mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}, Full list of Sinopharm NVSI authorizations
- SARS-CoV-2
v. t. e. The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, [2] the Sinopharm COVID-19 vaccine, [3] or BIBP vaccine, [3] [4] [5] is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm 's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, [6] resulting ...
- Zhong'aikewei (Chinese: 众爱可维), Hayat-Vax
- SARS-CoV-2
- 新冠肺炎-疫苗資訊最前線
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [1] [2] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [3] .
- History
- Combination Vaccines with Acellular Pertussis
- Related Combination Vaccines
- Contraindications
- Side Effects
- Immunization Schedules and Requirements
- Brand Names
- Further Reading
- External Links
Diphtheria and tetanus toxoids and whole-cell pertussis (DTP; now also "DTwP" to differentiate from the broader class of triple-combination vaccines) vaccination was licensed in 1949.Since the introduction of the combination vaccine, there has been an extensive decline in the incidence of pertussis, or whooping cough, the disease which the vaccine ...
DTaP and Tdap are both combination vaccinesagainst diphtheria, tetanus, and pertussis. The lower-case "d" and "p" indicate smaller concentrations of diphtheria toxoids and pertussis antigens, and "a" in "ap/aP" indicates that the pertussis toxoids are acellular.
Excluding pertussis
DT and Td vaccines lack the pertussis component. The Td vaccine is administered to children over the age of seven as well as to adults. It is most commonly administered as a booster shot every 10 years. The Td booster shot may also be administered as protection from a severe burn or dirty wound.The DT vaccine is given to children under the age of seven, who are unable to receive the pertussis antigen in the DTaP vaccine due to a contraindication.
Additional targets
In the United States, a combined inactivated polio (IPV), DTaP, and hepatitis B DTaP-IPV-HepB vaccine is available for children. In the UK, all babies born on or after 1 August 2017 are offered a hexavalent vaccine: DTaP, IPV, Haemophilus influenzae, and hepatitis B (DTaP-Hib-HepB-IPV in short). As of 2023, most of the DTP vaccine procured by UNICEF is of the DTwP-HepB-Hib(pentavalent whole-cell) type. The UNICEF plans to procure the DTwP-HepB-Hib-IPV (hexavalent whole-cell) vaccine starting...
The DPT vaccine should be avoided in persons who experienced a severe allergic reaction, such as anaphylaxis, to a past vaccine containing tetanus, diphtheria, or pertussis. It should also be avoided in persons with a known severe allergy to an ingredient in the vaccine. If the reaction was caused by tetanus toxoids, the CDC recommends considering ...
DTaP
Common side effects include soreness where the shot was given, fever, irritability, tenderness, loss of appetite, and vomiting. Most side effects are mild to moderate and may last from one to three days. More serious but rare reactions after a DTaP vaccination may include seizures, lowered consciousness, or a high fever over 105 °F (41 °C).Allergic reactions are uncommon, but are medical emergencies. Signs of an allergic reaction include hives, dyspnea, wheezing, swelling of face and throat,...
Tdap
Common side effects include pain or swelling where the shot was given, mild fever, headache, tiredness, nausea, vomiting, diarrhea, and stomach ache.Allergic reactions are possible and have the same presentation and indications as described above for allergic reactions in DTaP. Any individual who has experienced a life-threatening allergic reaction after receiving a previous dose of diphtheria, tetanus, or pertussis containing vaccine should not receive the Tdap vaccination. In pregnant women...
France
In France, children are given DTaP-Hib-HepB-IPV vaccines at 2 months (first dose) and 4 months (second dose) with a booster at 11 months.
Netherlands
In the Netherlands, pertussis is known as kinkhoestand DKTP refers to the DTaP-IPV combination vaccine against diphtheria, kinkhoest, tetanus, and polio. DTaP is given as part of the National Immunisation Programme.
United Kingdom
In the United Kingdom, Td/IPV is called the "3-in-1 teenage booster" and protects against tetanus, diphtheria and polio. It is given by the NHS to all teenagers aged 14 (the hexavalent vaccine is given to infants and provides the first stage of protection against diphtheria, tetanus, and polio, as well as pertussis, Haemophilus influenzae type B and hepatitis B). Subsequent boosters are recommended for foreign travellers where more than 10 years has passed since their last booster.This is pro...
United Kingdom
Brand names in the United Kingdom include Revaxis (Sanofi Pasteur).
United States
As of January 2020[update], there are six DTaP vaccines and two Tdap vaccines licensed and available for use in the United States.All of them are indicated as childhood vaccinations with the schedules as follows:
Diphtheria
1. World Health Organization (2009). The immunological basis for immunization : module 2: diphtheria — update 2009. World Health Organization (WHO). hdl:10665/44094. ISBN 9789241597869. 2. Ramsay M, ed. (2013). "Chapter 15: Diphtheria". Immunisation against infectious disease. Public Health England. 3. Roush SW, Baldy LM, Hall MA, eds. (March 2019). Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: U.S. Centers for Disease Control and Prevention(CDC).
Pertussis
1. World Health Organization (2017). The immunological basis for immunization series: module 4: pertussis, update 2017. World Health Organization (WHO). hdl:10665/259388. ISBN 9789241513173. 2. Ramsay M, ed. (2013). "Chapter 24: Pertussis". Immunisation against infectious disease. Public Health England. 3. Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 16: Pertussis". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. Centers for Disease Contr...
Tetanus
1. World Health Organization (2018). The immunological basis for immunization series: module 3: tetanus: update 2018. World Health Organization (WHO). hdl:10665/275340. ISBN 9789241513616. 2. Ramsay M, ed. (2013). "Chapter 30: Tetanus". Immunisation against infectious disease. Public Health England. 3. Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 21: Tetanus". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. Centers for Disease Control and...
"Tdap — Tetanus-Diphtheria-Pertussis Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). August 2021."DTaP (Diphtheria, Tetanus, Pertussis) Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). August 2021."DTaP/Tdap/Td ACIP Vaccine Recommendations". U.S. Centers for Disease Control and Prevention (CDC). 28 January 2020.Tetanus Toxoid at the U.S. National Library of Medicine Medical Subject Headings(MeSH)- Adacel, Boostrix, Revaxis, others
- Vaccine
- Vaccine
- Intramuscular injection
Human papillomavirus infection ( HPV infection) is caused by a DNA virus from the Papillomaviridae family. [5] Many HPV infections cause no symptoms and 90% resolve spontaneously within two years. [1] In some cases, an HPV infection persists and results in either warts or precancerous lesions. [2] These lesions, depending on the site affected ...
The COVID-19 pandemic, also known as the coronavirus pandemic, is a global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The novel virus was first identified in an outbreak in Wuhan, the capital of Hubei, China, in December 2019, before it spread to other areas of Asia, and then worldwide in early 2020.
